Shandong Operating Income vs Total Revenue Analysis

600529 Stock

24.41 0.19 0.77%

Shandong Pharmaceutical financial indicator trend analysis is much more than just breaking down Shandong Pharmaceutical prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Shandong Pharmaceutical is a good investment. Please check the relationship between Shandong Pharmaceutical Operating Income and its Total Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shandong Pharmaceutical Glass. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Operating Income vs Total Revenue

Operating Income vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Shandong Pharmaceutical Operating Income account and Total Revenue. At this time, the significance of the direction appears to have totally related.

The correlation between Shandong Pharmaceutical's Operating Income and Total Revenue is 0.99. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Shandong Pharmaceutical Glass, assuming nothing else is changed. The correlation between historical values of Shandong Pharmaceutical's Operating Income and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Shandong Pharmaceutical Glass are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Operating Income i.e., Shandong Pharmaceutical's Operating Income and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Shandong Pharmaceutical operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Shandong Pharmaceutical Glass is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Revenue

Total revenue comprises all receipts Shandong Pharmaceutical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Shandong Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Shandong Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shandong Pharmaceutical Glass. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

As of January 8, 2025, Selling General Administrative is expected to decline to about 177.4 M. In addition to that, Tax Provision is expected to decline to about 91.6 M

	2022	2023	2024	2025 (projected)
Operating Income	707.2M	898.9M	1.0B	1.1B
Total Revenue	4.2B	5.0B	5.7B	6.0B

Operating Income Total Revenue

Shandong Pharmaceutical fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Net Receivables	Inventory	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Other Assets	Other Liab	Short Term Investments	Net Tangible Assets	Other Stockholder Equity	Long Term Investments	Total Current Assets	Non Current Assets Total	Non Currrent Assets Other	Non Current Liabilities Total	Short Long Term Debt
Total Assets		0.27	0.98	1.0	0.99	0.97	0.94	-0.38	0.66	0.98	0.33	0.98	0.95	0.95	0.98	0.96	0.92	0.91	0.88	0.88	-0.67	0.9	0.88	0.32	0.85	0.37
Other Current Liab	0.27		0.31	0.25	0.32	0.29	0.38	-0.1	0.13	0.34	0.42	0.31	0.43	0.32	0.23	0.23	0.34	0.29	0.31	0.35	0.08	0.31	0.19	0.7	0.29	0.66
Total Current Liabilities	0.98	0.31		0.97	0.99	1.0	0.92	-0.44	0.67	0.98	0.41	1.0	0.95	0.98	0.99	0.94	0.96	0.84	0.86	0.91	-0.59	0.87	0.89	0.44	0.9	0.48
Total Stockholder Equity	1.0	0.25	0.97		0.98	0.96	0.94	-0.37	0.66	0.98	0.31	0.97	0.94	0.94	0.97	0.95	0.9	0.92	0.88	0.87	-0.68	0.9	0.88	0.29	0.83	0.34
Retained Earnings	0.99	0.32	0.99	0.98		0.99	0.94	-0.41	0.66	0.98	0.35	1.0	0.97	0.98	0.98	0.94	0.96	0.86	0.87	0.91	-0.6	0.88	0.89	0.41	0.89	0.47
Accounts Payable	0.97	0.29	1.0	0.96	0.99		0.91	-0.45	0.67	0.97	0.42	1.0	0.94	0.97	0.99	0.94	0.95	0.83	0.85	0.9	-0.58	0.86	0.88	0.45	0.89	0.48
Cash	0.94	0.38	0.92	0.94	0.94	0.91		-0.34	0.58	0.9	0.32	0.93	0.95	0.93	0.89	0.84	0.89	0.86	0.84	0.87	-0.58	0.87	0.8	0.29	0.82	0.46
Long Term Debt	-0.38	-0.1	-0.44	-0.37	-0.41	-0.45	-0.34		-0.82	-0.46	-0.43	-0.42	-0.31	-0.44	-0.46	-0.26	-0.44	-0.21	-0.28	-0.29	0.02	-0.29	-0.25	-0.14	-0.26	-0.23
Net Receivables	0.66	0.13	0.67	0.66	0.66	0.67	0.58	-0.82		0.7	0.2	0.66	0.59	0.64	0.68	0.59	0.65	0.56	0.71	0.65	-0.14	0.71	0.66	0.21	0.54	0.21
Inventory	0.98	0.34	0.98	0.98	0.98	0.97	0.9	-0.46	0.7		0.4	0.98	0.93	0.95	0.98	0.95	0.93	0.86	0.87	0.87	-0.6	0.87	0.88	0.42	0.85	0.39
Other Current Assets	0.33	0.42	0.41	0.31	0.35	0.42	0.32	-0.43	0.2	0.4		0.4	0.28	0.48	0.43	0.26	0.38	0.19	0.22	0.33	-0.11	0.2	0.22	0.51	0.38	0.51
Total Liab	0.98	0.31	1.0	0.97	1.0	1.0	0.93	-0.42	0.66	0.98	0.4		0.96	0.98	0.99	0.94	0.96	0.85	0.86	0.91	-0.59	0.87	0.89	0.45	0.9	0.49
Intangible Assets	0.95	0.43	0.95	0.94	0.97	0.94	0.95	-0.31	0.59	0.93	0.28	0.96		0.95	0.92	0.9	0.94	0.86	0.86	0.91	-0.56	0.88	0.86	0.42	0.88	0.53
Common Stock	0.95	0.32	0.98	0.94	0.98	0.97	0.93	-0.44	0.64	0.95	0.48	0.98	0.95		0.97	0.89	0.97	0.81	0.84	0.92	-0.57	0.84	0.86	0.41	0.92	0.52
Property Plant Equipment	0.98	0.23	0.99	0.97	0.98	0.99	0.89	-0.46	0.68	0.98	0.43	0.99	0.92	0.97		0.94	0.95	0.82	0.85	0.88	-0.62	0.85	0.89	0.39	0.89	0.39
Other Assets	0.96	0.23	0.94	0.95	0.94	0.94	0.84	-0.26	0.59	0.95	0.26	0.94	0.9	0.89	0.94		0.86	0.86	0.87	0.85	-0.63	0.87	0.9	0.43	0.83	0.29
Other Liab	0.92	0.34	0.96	0.9	0.96	0.95	0.89	-0.44	0.65	0.93	0.38	0.96	0.94	0.97	0.95	0.86		0.74	0.81	0.89	-0.52	0.8	0.84	0.44	0.91	0.54
Short Term Investments	0.91	0.29	0.84	0.92	0.86	0.83	0.86	-0.21	0.56	0.86	0.19	0.85	0.86	0.81	0.82	0.86	0.74		0.82	0.78	-0.65	0.87	0.77	0.19	0.67	0.36
Net Tangible Assets	0.88	0.31	0.86	0.88	0.87	0.85	0.84	-0.28	0.71	0.87	0.22	0.86	0.86	0.84	0.85	0.87	0.81	0.82		0.96	-0.33	0.99	0.97	0.43	0.88	0.37
Other Stockholder Equity	0.88	0.35	0.91	0.87	0.91	0.9	0.87	-0.29	0.65	0.87	0.33	0.91	0.91	0.92	0.88	0.85	0.89	0.78	0.96		-0.34	0.95	0.96	0.5	0.96	0.54
Long Term Investments	-0.67	0.08	-0.59	-0.68	-0.6	-0.58	-0.58	0.02	-0.14	-0.6	-0.11	-0.59	-0.56	-0.57	-0.62	-0.63	-0.52	-0.65	-0.33	-0.34		-0.37	-0.38	0.17	-0.36	0.03
Total Current Assets	0.9	0.31	0.87	0.9	0.88	0.86	0.87	-0.29	0.71	0.87	0.2	0.87	0.88	0.84	0.85	0.87	0.8	0.87	0.99	0.95	-0.37		0.95	0.38	0.86	0.37
Non Current Assets Total	0.88	0.19	0.89	0.88	0.89	0.88	0.8	-0.25	0.66	0.88	0.22	0.89	0.86	0.86	0.89	0.9	0.84	0.77	0.97	0.96	-0.38	0.95		0.43	0.93	0.32
Non Currrent Assets Other	0.32	0.7	0.44	0.29	0.41	0.45	0.29	-0.14	0.21	0.42	0.51	0.45	0.42	0.41	0.39	0.43	0.44	0.19	0.43	0.5	0.17	0.38	0.43		0.53	0.67
Non Current Liabilities Total	0.85	0.29	0.9	0.83	0.89	0.89	0.82	-0.26	0.54	0.85	0.38	0.9	0.88	0.92	0.89	0.83	0.91	0.67	0.88	0.96	-0.36	0.86	0.93	0.53		0.54
Short Long Term Debt	0.37	0.66	0.48	0.34	0.47	0.48	0.46	-0.23	0.21	0.39	0.51	0.49	0.53	0.52	0.39	0.29	0.54	0.36	0.37	0.54	0.03	0.37	0.32	0.67	0.54

Click cells to compare fundamentals

Shandong Pharmaceutical Account Relationship Matchups

Shandong Pharmaceutical fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	5.6B	6.4B	8.8B	9.3B	10.7B	11.3B
Other Current Liab	156.5M	117.6M	324.5M	69.9M	80.4M	131.4M
Total Current Liabilities	1.3B	1.7B	1.8B	1.7B	2.0B	2.1B
Total Stockholder Equity	4.3B	4.7B	7.0B	7.5B	8.7B	9.1B
Retained Earnings	2.7B	3.1B	3.5B	3.6B	4.1B	4.3B
Accounts Payable	995.8M	1.4B	1.4B	1.4B	1.6B	1.7B
Cash	1.1B	885.0M	1.4B	1.5B	1.7B	1.8B
Net Receivables	640.8M	764.4M	871.7M	970.1M	1.1B	622.7M
Inventory	749.2M	877.7M	1.2B	1.1B	1.2B	1.3B
Other Current Assets	82.5M	62.0M	104.6M	35.0M	40.3M	76.8M
Total Liab	1.4B	1.7B	1.8B	1.8B	2.1B	2.2B
Intangible Assets	203.3M	198.4M	260.4M	253.7M	291.7M	306.3M
Property Plant Equipment	1.9B	2.1B	2.6B	2.8B	3.2B	3.4B
Other Assets	64.4M	161.3M	319.4M	381.9M	439.2M	461.2M
Other Liab	49.7M	60.0M	60.0M	58.9M	67.8M	71.2M
Short Term Investments	230.5M	307.1M	1.1B	1.2B	1.4B	1.5B
Net Tangible Assets	3.7B	4.1B	4.5B	6.7B	7.7B	4.2B
Other Stockholder Equity	62.2M	64.4M	66.2M	75.5M	86.8M	59.8M
Total Current Assets	3.1B	3.3B	5.3B	5.5B	6.4B	3.7B
Non Current Assets Total	2.5B	3.1B	3.5B	3.8B	4.3B	2.7B
Non Currrent Assets Other	131.7M	287.0M	349.9M	16.8M	19.3M	18.3M
Non Current Liabilities Total	60.0M	60.0M	58.9M	57.6M	66.3M	51.7M
Net Invested Capital	4.3B	4.7B	7.0B	7.5B	8.7B	5.4B
Net Working Capital	1.8B	1.7B	3.6B	3.8B	4.4B	2.6B
Property Plant And Equipment Net	2.1B	2.6B	2.8B	3.5B	4.0B	2.8B
Property Plant And Equipment Gross	3.2B	3.8B	2.8B	5.2B	5.9B	3.9B

Currently Active Assets on Macroaxis

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin
ADA	Cardano
XRP	XRP

Other Information on Investing in Shandong Stock

Balance Sheet is a snapshot of the financial position of Shandong Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Shandong Pharmaceutical Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Shandong Pharmaceutical and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Shandong currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Shandong Operating Income vs Total Revenue Analysis

Operating Income vs Total Revenue

Operating Income vs Total Revenue Correlation Analysis

Correlation Coefficient

Operating Income

Total Revenue

Shandong Pharmaceutical fundamental ratios Correlations

Shandong Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Shandong Pharmaceutical fundamental ratios Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Shandong Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Retained Earnings
Total Liab	+ 1.0	Accounts Payable
Retained Earnings	+ 0.99	Total Assets

Net Receivables	- 0.82	Long Term Debt
Long Term Investments	- 0.68	Total Stockholder Equity
Long Term Investments	- 0.67	Total Assets
Long Term Investments	- 0.65	Short Term Investments
Long Term Investments	- 0.63	Other Assets
Long Term Investments	- 0.62	Property Plant Equipment